Life-Science Tools & Sequencing

Analysts lifted their fair value estimate for Tecan Group from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Berenberg sits at the top of the range with a CHF 240 price target and a Buy rating, while Deutsche Bank raised its target in several steps from CHF 138 to CHF 151, then CHF 176, and most recently CHF 198, maintaining a Hold rating. Morgan Stanley moved its target from CHF 142 to CHF 160 and then to CHF 178 while keeping an Equal Weight stance, and Oddo BHF downgraded the stock to Neutral from Outperform with a CHF 192 target. The revised fair value reflects revenue growth assumptions of 5.53%, down from 5.56%, a net profit margin of 9.57% versus 9.70%, a future P/E of 27.00x versus 23.49x, and a discount rate of 4.90% versus 4.82%.

Agilent Technologies Inc. announced the launch of the Agilent BioTek Gen5 AI cell identification module, a new image analysis software add-on that brings AI-based cell identification and segmentation into BioTek Gen5 imaging analysis. Developed for use with compatible Agilent BioTek automated imaging systems, the module performs AI-based segmentation without requiring conventional threshold setting or parameter tuning, and is designed to reduce manual image-analysis steps and support consistent cell counting and confluence analysis. The module supports label-free and fluorescence, live-cell and kinetic assays, and its integration with Gen5 lets researchers using compatible BioTek Cytation and Lionheart automated imagers apply AI-based segmentation within their existing imaging assays. Xavier Amouretti, vice president and BioTek business unit leader at Agilent, said the module brings AI-based segmentation directly into the established BioTek imaging workflow to reduce the effort associated with image analysis. Agilent, which generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide, said the launch expands the image-analysis capabilities available within Gen5 and reflects its focus on integrating automation and AI into laboratory workflows.

Thermo Fisher Scientific Inc. announced on September 23 the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel lets development teams rapidly evaluate and optimize upstream bioprocesses, and in a 14-day fed-batch study select panel combinations yielded up to 73% higher antibody titer and up to 202% higher peak viable cell density compared to benchmark media. The release follows Thermo Fisher's second-quarter 2026 results, in which revenue grew 10% year-over-year to $11.99 billion on 5% organic growth, GAAP diluted EPS expanded 9% to $4.68, and adjusted EPS rose 13% to $6.03. Second-quarter adjusted operating income reached $2.73 billion, a 22.8% adjusted operating margin with 80 basis points of year-over-year expansion, and the company repurchased $1.0 billion of shares in the quarter while opening its U.S. Bioprocess Design Center in Plainville, Massachusetts. Thermo Fisher's GAAP operating margin stood at 17.4% in the second quarter of 2026, still below its 2021-2022 historic peak levels, and the planned divestiture of its microbiology business introduces a near-term revenue drag that new bioprocess launches must work to replace.

Gilead Sciences and Thermo Fisher Scientific each raised their full-year outlooks after reporting stronger quarterly results, though their growth profiles differ sharply. Gilead's second-quarter product sales excluding Veklury rose 10% to $7.6 billion, with HIV sales up 12% to $5.7 billion, Biktarvy up 7% to $3.8 billion, Descovy up 48% to $967 million, and Yeztugo generating $232 million versus $15 million a year earlier, prompting management to guide 2026 product sales of $30.1 billion to $30.4 billion and product sales excluding Veklury of $29.8 billion to $30.1 billion. Thermo Fisher reported fiscal second-quarter revenue up 10% to $11.99 billion, including 5% organic growth, with adjusted EPS up 13% to $6.03 and adjusted operating margin expanding to 22.8% from 21.9%, and raised its full-year adjusted EPS outlook to $24.93 to $25.33 from $24.64 to $25.12. Gilead's growth carries concentration risk, as HIV accounted for $5.69 billion of its $7.63 billion in quarterly product sales, while $11.2 billion in acquired in-process R&D tied to the Arcellx, Tubulis and Ouro Medicines deals drove GAAP and non-GAAP losses per share of $8.45 and $6.75. Thermo Fisher's broader base depends on a durable recovery in customer spending, with organic growth accelerating from 1% in the first quarter to 5% and China returning to growth even as academic and government demand there remained subdued.

Mission Bio announced that Merck & Co. and Incyte will each present new data generated using its Assay Services and Tapestri Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit, alongside a third presentation from Mission Bio itself featuring new clinical data in acute myeloid leukemia. Merck scientist Sydney Hart will present functional genomics findings from a targeted DNA and RNA single-cell assay built with Mission Bio's Assay Services team to study how CRISPR-edited genetic variants affect immune cell function in autoimmune and inflammatory disease, work that links target validation to drug development decision-making. Incyte's Erin Crowgey will present new single-cell clinical data on INCA033989, a monoclonal antibody targeting mutant calreticulin-positive cells in essential thrombocythemia and myelofibrosis, generated with a custom Tapestri assay measuring 46 proteins and 37 genes in the same cell, showing depletion of mutant CALR-positive cells and repopulation by wild-type cells with relevant clinical improvements. Mission Bio Chief Medical Officer Zivjena Vucetic will present clinical study data showing single-cell multiomics achieved 93% sensitivity for measurable residual disease in AML compared to 43% for flow cytometry and 71% for other molecular methods, with additional evidence supporting more accurate stratification of relapse-free survival. The three presentations illustrate how single-cell multiomics connects genetic variation to cellular function, characterizes treatment response in individual cell populations, and identifies residual disease with greater resolution across drug development pipelines.

Agilent Technologies shares have gained about 9.6% in the month since its third-quarter fiscal 2026 earnings report, outperforming the S&P 500. The company reported non-GAAP earnings of $1.62 per share, up 18% year over year and beating the Zacks Consensus Estimate by 9.46%, while revenues of $1.88 billion rose 8.1% on a reported basis and 7.3% on a core basis, surpassing the consensus mark by 2.08%. Strength reflected broad demand across pharma and China, with the Advanced Therapeutics Division growing nearly 30% and instrument book-to-bill above 1.0 for the 10th consecutive quarter. For the fourth quarter of fiscal 2026, Agilent expects revenues of $1.98-$2.00 billion, implying reported growth of 6.4-7.4% and core growth of 5.2-6.2%, with non-GAAP earnings of $1.71-$1.74 per share. For the full fiscal year, revenues are projected at $7.49-$7.51 billion, representing reported growth of 7.8-8.1%, and non-GAAP earnings are expected at $6.18-$6.21 per share, up 15 cents at the midpoint from the prior guide.

The global cell isolation and cell separation market is projected to grow from USD 6.97 billion in 2026 to USD 13.51 billion by 2032, a compound annual growth rate of 11.39%, according to a new report from ResearchAndMarkets.com. The report profiles major players including Thermo Fisher Scientific, Bio-Rad Laboratories, Beckman Coulter, and Sartorius AG. Growth is driven by demand for high-purity, viable cells for single-cell sequencing, flow cytometry, and adoptive cell therapy, with the industry shifting from manual, open protocols toward automated, closed, digitally controlled systems. Artificial intelligence is cited as improving image-based cell recognition, flow cytometry gating, and quality control, while North America leads regional demand and Asia-Pacific expands through biotechnology and genomics investment in China, India, Japan, South Korea, and Australia.

Agilent Technologies executives said the company's growth has accelerated to nearly 10% to 11% from roughly flat two years ago, with operating margin up more than 100 basis points despite tariff headwinds, as they outlined drivers including China, instrument replacement cycles and lab automation at a J.P. Morgan conference. Chief Executive Officer Padraig McDonnell said China delivered broad-based strength in the fiscal third quarter, with double-digit growth in pharma and food and high-teens growth in advanced materials, and management expects the country to be a mid- to high-single-digit long-term growth market. Agilent is less than halfway through its liquid chromatography replacement cycle, which it estimates could add 200 to 300 basis points to the overall business, and about one-quarter through its gas chromatography cycle, worth roughly 100 basis points of growth. The advanced therapeutics CDMO business grew 30% in the fiscal third quarter, and Chief Financial Officer Adam Elinoff said Train C is expected to begin operations in spring 2027 and is 75% booked for next year, with Train C and Train D together roughly doubling site revenue to about $300 million at full capacity. McDonnell said Agilent has begun booking its first reshoring and onshoring orders, with five of the top 10 pharmaceutical companies placing orders, supporting a projected $300 million opportunity by 2030 that represents about one-third of an estimated $1 billion market opportunity.

Twist Bioscience Corporation confirmed on September 16 a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company, under which Twist will provide antibody characterization data services. Twist will also supply data to support AbLab, an antibody developability prediction model, along with high-throughput wet-lab data used to train and improve those models. Through the agreement, TuneLab users will be able to order Twist's antibody services using preferred Twist protocols, generating wet-lab data that can support AI-enabled antibody discovery. The companies did not disclose a minimum purchase commitment, contract value, or specific revenue guidance, and the announcement includes no rights to Lilly drug candidates, milestone payments, or royalties, so the near-term financial impact depends on how much TuneLab users ultimately purchase Twist's services. According to Insider Monkey's database, the number of hedge funds holding Twist rose to 42 in the second quarter from 30 in the first quarter, with Ark Investment Management cutting its position by 29% to $468.1 million, Farallon Capital raising its stake by 50% to $219.79 million, and DE Shaw increasing its position by 2,442% to $121.98 million, while short interest fell to 12.07 million shares as of August 31 from 14.08 million as of July 31 but remained elevated at approximately 18.20%.

Agilent Technologies Inc. announced the launch of the Agilent 4150 TapeStationDx system, the Agilent 4200 TapeStationDx system and Agilent TapeStationDx software, extending its automated electrophoresis portfolio into regulated clinical laboratory environments. The new CE-IVD-labeled systems and software are designed to support standardized and traceable quality control of DNA and RNA samples used in clinical next-generation sequencing workflows, and Agilent said it is among the first providers to offer CE-IVD-labeled automated electrophoresis solutions for clinical NGS sample quality control in the launch regions. The 4150 TapeStationDx system supports lower-throughput laboratories with the flexibility to analyze 1 to 16 samples using tube strips, while the 4200 TapeStationDx system provides scalable throughput from 1 to 96 samples using either tube strips or 96-well plates at a constant cost per sample, with both systems delivering automated sample quality control in approximately 1 to 2 minutes per sample. The accompanying TapeStationDx software controls data acquisition and analysis and includes reporting and data export capabilities, with data integrity features such as audit trails and electronic signatures to help laboratories support compliance with regulations including 21 CFR Part 11 and EU Annex 11. The systems and software are available in the United States, Canada and select European markets including Austria, Belgium, Luxembourg, Switzerland, Germany, Denmark, Spain, Finland, France, the United Kingdom, Ireland, Italy, the Netherlands and Sweden, and Agilent will showcase the portfolio at the Italian Society of Human Genetics National Congress, the American Society of Human Genetics Annual Meeting and the Association for Molecular Pathology Annual Meeting.

Tempus AI is building a research platform based on 100,000 whole genomes linked to long term clinical records, a project that follows its $1.5 billion acquisition of Personalis. The Personalis deal strengthens Tempus' position in molecular residual disease testing, expanding the company from diagnosing and selecting cancer treatments into monitoring patients for cancer recurrence. The new whole genome project arrives after a sharp run in the shares, with a 90 day share price return of 62.68% and a 7 day gain of 31.91%, though the 1 year total shareholder return shows an 11.79% decline. Tempus AI closed at $77.84 against a narrative fair value estimate of $75.68, a level at which 26 investors see the stock as 3% overvalued. The company still carries ongoing losses and meaningful debt, so any setback integrating Personalis could quickly challenge the upbeat narrative.

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.

IP Group PLC reported that its net asset value exceeded GBP1 billion at the end of H1 2026, with NAV per share rising about 3% to 114p and reaching roughly 117p as of 11 September 2026. The company generated GBP69 million in cash proceeds during the half, up from GBP30 million a year earlier, plus GBP17 million after the period, bringing year-to-date proceeds to about GBP86 million and total proceeds since 2025 to GBP154 million, more than halfway toward its GBP250 million target by the end of 2027. Gross cash stood at GBP239 million at period end, while the portfolio was valued at roughly GBP900 million, or about 103p per share, with the top five assets accounting for about 50p per share. The Pfizer royalty interest rose GBP27 million to just over GBP150 million, and Oxford Nanopore posted GBP117 million in revenue, about 12% growth at constant currency, with gross margin up 400 basis points to 62% and its adjusted EBITDA loss more than halved to just over GBP22 million. Profit for the period was GBP31 million, effectively converted into cash, and about GBP50 million of proceeds is available for shareholder returns under the capital allocation policy.

S&P Dow Jones Indices announced on September 4, 2026, that Bloom Energy and Illumina are joining the S&P 500 benchmark, with the changes taking effect before trading opens on September 21, 2026, replacing Molson Coors, The Trade Desk, and Builders FirstSource. Bloom Energy arrives after product revenue jumped 215% last quarter on hyperscaler demand for onsite fuel-cell capacity, and management raised full-year revenue guidance to $3.9 billion to $4.2 billion. Illumina returns to the index with second-quarter revenue up 9% and raised EPS guidance of $5.30 to $5.40, though management flagged ongoing China and tariff headwinds. The swap barely moves returns for the Vanguard S&P 500 ETF, since new S&P 500 entrants typically begin well under a tenth of a percent of the index, while Vanguard's June 30, 2026 factsheet showed 38% of the fund in its ten largest holdings, including 8% in NVIDIA alone. The composition shift tilts the index toward growth at the margin, with Bloom carrying a beta of 3.81 and a forward P/E of 57x and Illumina at a forward P/E of 34x, while the departing Molson Coors trades at 7x forward earnings with a 4.9% dividend yield and Builders FirstSource at 14x.

Twist Bioscience and Ginkgo Bioworks traded higher on Wednesday after each announced agreements with Lilly TuneLab, a collaborative drug discovery platform established by Eli Lilly. Under its agreement, Twist Bioscience said it will provide antibody characterization data services to TuneLab companies accessing AI and machine learning drug discovery models trained on Lilly-owned research data. CEO Emily Leproust said Twist has the scale and high-throughput capabilities to generate consistent and reliable antibody characterization data these models need to be trained on. Ginkgo Bioworks, through its Ginkgo Datapoints offering, will provide discovery data generation services to TuneLab users. John Androsavich, General Manager at Ginkgo Datapoints, said layering on Ginkgo's ability to quickly generate high-quality, AI-ready datasets at any scale should let TuneLab participants close the loop between digital design and biological reality faster than ever before.

Twist Bioscience Corporation announced an agreement with Lilly TuneLab, the collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under the deal, Twist will serve as a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab users will be able to order antibody services from Twist using TuneLab preferred Twist protocols to generate high-quality wet lab data, connecting experimental data with AI-enabled discovery. Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, said the company has the scale and high-throughput capabilities to generate the consistent, reliable antibody characterization data these models need to be trained on. Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D.

The global nucleic acid isolation and purification market is projected to grow from USD 5.41 billion in 2026 to USD 10.52 billion by 2035, a compound annual growth rate of 6.9%, according to a new report from ResearchAndMarkets.com. Growth is being driven by demand for molecular diagnostics, next-generation sequencing, personalized medicine, genomics research and advanced drug discovery, with magnetic bead-based purification, automated extraction platforms and microfluidic systems improving processing speed and throughput. Approximately 370 companies currently offer nucleic acid isolation and purification products worldwide, with nearly 45% based in the Asia-Pacific region, and kits account for approximately 65% of the market. North America holds more than 40% of the global market, while the United States alone is expected to account for approximately 30% and expand at a CAGR of 6.8% through 2035. The report profiles key players including Roche, Promega, Macherey-Nagel, Bio-Rad, Danaher, Merck KGaA, Norgen Biotek, Perkin Elmer, Qiagen and Thermo Fisher Scientific.

Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC, a Mayo Clinic-controlled company that will build one of the world's leading biomedical datasets to identify signs of disease before symptoms appear. Mayo Clinic will serve as majority owner and Thermo Fisher joins as minority owner of the venture, which will generate molecular data from one million biospecimens linked with longitudinal clinical information collected over several years. The effort integrates proteomic, genomic and clinical data, with Thermo Fisher contributing its Olink Explore HT proteomics platform and Thermo Scientific Orbitrap Mass Spectrometry, kits and reagents. Precure, LLC complements Precure Research, Mayo Clinic's investigator-led scientific effort, by providing the scale, infrastructure and collaborations needed to generate population-scale molecular data and translate discoveries into new diagnostics, therapeutics and other healthcare solutions. Mayo Clinic said any financial returns from its involvement would be reinvested in its nonprofit mission of patient care, research and education.

Bangkok Genomics Innovation Public Company Limited, or BKGI, reported total revenue of 386.73 million baht for 2025, an increase of 40.86 million baht, or 11.81%, from the previous year, driven by revenue from sales of laboratory products, which came in at 111.87 million baht, up 37.96%, while service revenue rose 4.34%, amid competition and changes in reimbursement policy for prenatal chromosomal abnormality screening services. Dr. Saowalak Dansakul, Chief Executive Officer of BKGI, said the company aims to drive its Genomics and Precision Medicine business in line with the policy of pushing Thailand toward becoming an international health hub, or Medical Hub, and with the trend toward preventive medicine. The company is preparing for opportunities in the Genomics Thailand Phase 2 project and is laying out a B2B business model in the Wellness and Longevity market to support clinics and partners with genetic testing products and genetic counseling personnel. For the second half of the year, the company expects support from the gradual recognition of revenue from sales of test reagents following delivery of Sequencing, or NGS, machines, as well as steady revenue from the Oncology services group reimbursed through benefits of the National Health Security Office, or NHSO. Meanwhile, data from the National Statistical Office indicates that in 2024 Thailand had 13.68 million people aged 60 and over, up from 11.63 million in 2020, a structural factor supporting the preventive health market.

Tempus AI announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years, with a long-term goal of reaching one million genomes. The company said the effort will create the first de-identified multimodal whole-genome sequencing dataset built around disease populations and patient outcomes and specifically optimized for AI-driven research. The new dataset will be integrated into Tempus' existing de-identified multimodal data environment, where researchers can access genomic information alongside clinical histories, imaging, pathology and patient outcomes, and analyze it through Tempus Lens without moving datasets between systems. Development is already underway and the initial dataset is available through Tempus' Early Adopter Program, with additional members onboarded in waves and general availability planned for mid-2027. Founder and CEO Eric Lefkofsky said adding whole genome data linked to longitudinal outcomes gives researchers a richer foundation to build AI models and ultimately improve patient care.

MarketsandMarkets projects the global MRI systems market will grow from USD 6.88 billion in 2026 to USD 9.68 billion by 2031, at a CAGR of 7.0%. Growth is driven by the rising prevalence of neurological and musculoskeletal disorders, an expanding geriatric population, increasing chronic diseases like cancer, and supportive regulatory and reimbursement policies. The closed MRI systems segment held the largest market share in 2025, as did the fixed/stationary design segment. Asia Pacific is experiencing rapid growth, particularly in China, India, and Southeast Asia. Key players include Siemens Healthineers, GE HealthCare, Philips, FUJIFILM, and Canon, with innovations focusing on AI-enabled workflows and helium-free systems.

A new report from ResearchAndMarkets.com forecasts the global research use recombinant protein market to grow from $1.11 billion in 2026 to $1.55 billion by 2031, at a compound annual growth rate of 7.0%. The market's expansion is driven by growing recombinant therapeutic pipelines, increased preclinical research in advanced therapies, and rising demand for recombinant proteins in tumor microenvironment studies. Among species, human recombinant proteins are expected to record the highest CAGR, while cytokines and chemokines are projected to lead the market in 2026. The United States is forecast to register the highest CAGR, supported by advanced biomedical research infrastructure and high adoption in drug discovery. Key players include Thermo Fisher Scientific, Bio-Techne, Merck KGaA, Danaher, and Revvity.

S&P Dow Jones Indices announced that Bloom Energy, Everpure, and Illumina will join the S&P 500 before trading begins Monday, September 21, replacing Molson Coors Beverage, Trade Desk, and Builders FirstSource. Bloom Energy, the largest incoming company with a market capitalization of $74 billion, supplies fuel-cell systems for data centers and industrial facilities, offering exposure to AI-driven power demand. Everpure provides data-storage systems and software, while Illumina makes gene-sequencing tools. All three stocks have gained at least 40% in 2026. Index funds and ETFs tracking the benchmark must buy the new constituents and sell the departing companies, potentially boosting volume and price moves near the effective date. A parallel S&P 100 reshuffle will add Dell, Palo Alto Networks, Arista Networks, and SanDisk, while removing Honeywell Aerospace, Nike, Simon Property Group, and Colgate-Palmolive.

The global cardiovascular ultrasound system market is projected to grow from $1.73 billion in 2025 to $1.89 billion in 2026, a compound annual growth rate of 9.8%, and is forecast to reach $2.77 billion by 2030 at a CAGR of 10%, according to a new report from ResearchAndMarkets.com. Growth is driven by rising cardiovascular disease prevalence, demand for early non-invasive diagnostics, and adoption of AI-assisted imaging and portable devices. North America was the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region. Key developments include Royal Philips' August 2025 launch of Transcend Plus for its EPIQ CVx and Affiniti CVx systems, featuring FDA-cleared AI, and Philips' May 2023 acquisition of DiA Imaging Analysis for approximately $100 million to bolster AI-driven cardiac analysis. The report profiles major players including GE HealthCare, Siemens Healthineers, and Koninklijke Philips.

GE HealthCare announced on August 31 that its Photonova Spectra photon-counting CT scanner received CE Mark approval, enabling sales across Europe and other regions recognizing the certification, following US FDA 510(k) clearance and Japanese regulatory approval in March 2026. The scanner, built on proprietary Deep Silicon detector technology, rotates in 0.23 seconds, covers 80 millimeters per rotation, and processes up to 50 times more data than conventional CT scanners, with NVIDIA's accelerated computing platform to maintain workflow speed. The company is partnering with UZ Brussel and Rigshospitalet for clinical research in cardiology, oncology, and musculoskeletal imaging. In the quarter ended June 30, GE HealthCare posted record organic orders growth of 11.1%, a book-to-bill ratio of 1.15, and a backlog of $23.9 billion, with revenue reaching $5.3 billion, up 5.7%. However, Patient Care Solutions, a segment covering patient monitoring, saw revenue drop 13.3% and swung to a segment EBIT loss of $26 million, prompting a review of strategic options for that unit. Company-wide adjusted EBIT margin slipped 40 basis points to 14.2%, and management reaffirmed full-year guidance for organic revenue growth of 3.0% to 4.0% and adjusted earnings per share of $4.80 to $5.00.

Agilent Technologies raised its full-year fiscal 2026 earnings per share guidance to $6.18 to $6.21, excluding the net benefit of tariff refunds, earnings per share of $6.12 to $6.15 are now expected, after reporting third-quarter revenue of $1.88 billion, up 7.3% on a core basis, with China growing 9% despite minimal stimulus benefit. The company now expects full-year revenue of $7.49 billion to $7.51 billion, implying fourth-quarter revenue of $1.98 billion to $2 billion and EPS of $1.71 to $1.74. CEO Padraig McDonnell cited strong pharma growth of 12%, advanced therapeutics growth of nearly 30%, and competitive wins in China, while CFO Adam Elinoff noted Biocare contributed $10 million in Q3 and about $23 million in Q4 guidance. Management also highlighted a reshoring opportunity sized at about $1 billion through 2030, with orders secured from five of the top ten pharma companies, and expects revenue from reshoring to begin in fiscal 2027.

Masimo, a Danaher company, announced FDA 510(k) clearance for its Root with LiDCO hemodynamic monitoring solution, including the Masimo LiDCO sensor, enabling continuous monitoring of oxygen delivery. The system combines continuous noninvasive hemoglobin, Masimo SET oxygen saturation, and cardiac output to provide a beat-to-beat view of oxygen being delivered to tissue. Dr. Basil Matta, Chief Medical Officer at Masimo, said the technology gives clinicians a continuous view of oxygen delivery and helps them better understand changes in a patient's oxygen supply as they occur. Clinical studies cited by the company showed preoperative optimization of oxygen delivery reduced mortality from 17% to 3% in one trial, and another trial demonstrated a 75% reduction in 28-day mortality when targeting oxygen delivery greater than 600 mL/min/m².

Merck and Moderna announced positive topline Phase 3 results for their individualized cancer vaccine intismeran autogene in resected melanoma, beating Keytruda alone on recurrence-free survival, though no specific efficacy numbers have been released yet. The news lifted several biotech names, with BioNTech surging 21.6% on read-across excitement and Illumina rising 15.6% to $223.22 because its NovaSeq X sequencers are required for every individualized neoantigen dose manufactured. Pacific Biosciences gained 5.8% to $1.28, Repligen traded at $181.62 after reporting second-quarter revenue of $204 million with 13% organic growth, and Danaher saw mid-teens bioprocessing order growth in the second quarter. Leerink Partners analyst Daina Graybosch called the market reaction overly optimistic but still raised her 2032 intismeran forecast to $1.4 billion, while Morningstar projects $16.8 billion by 2035.

Abbott Laboratories and Thermo Fisher Scientific both reported encouraging quarterly results, with Abbott's diagnostics segment sales rising 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion. Abbott reaffirmed its full-year comparable sales growth guidance of 6.5% to 7.5%, while Thermo Fisher's organic revenue increased 5%, signaling a potential recovery in life sciences spending. Thermo Fisher's management highlighted improving customer activity across pharmaceutical and biotechnology markets, and its Analytical Instruments business returned to growth after nearly two years of weak demand. Abbott's diversified portfolio across diagnostics, medical devices, and nutrition provides resilience, while Thermo Fisher's outlook depends more heavily on continued recovery in pharmaceutical and biotechnology spending.

10x Genomics reported second-quarter revenue of $151 million, boosted by a $1.6 million settlement payment from Takara, while booked orders for its new Atera instrument platform already exceeded the roughly 40 units planned for all of 2026. Excluding the settlement, revenue grew just 3% year-over-year to $149.4 million, with consumables up 7% and spatial consumables climbing 16% on Xenium strength. Total instrument revenue fell 47% as customers delayed purchases of older systems, and management guided for a sequential revenue step down in the third quarter before a fourth-quarter jump. The company raised full-year revenue guidance to $610 million to $630 million, and cash and marketable securities rose to $552 million. 10x also acquired Proteintech Genomics and announced research partnerships with Cleveland Clinic and Lausanne University Hospital.

Thermo Fisher Scientific received FDA 510(k) clearance for its EXENT Solution, an automated mass spectrometry platform for multiple myeloma. The clearance was highlighted at the ADLM conference in Anaheim in late July 2026, alongside the EliA CTD 13 Screen for autoimmune connective tissue diseases. The EXENT clearance strengthens Thermo Fisher's specialty diagnostics presence in oncology and supports its strategy of linking high-complexity diagnostics with integrated software and standardized clinical decision support. The company's investment narrative projects $54.1 billion in revenue and $9.5 billion in earnings by 2029, requiring 6.2% annual revenue growth from a current earnings base of $6.8 billion.

The global bioinformatics market is projected to grow from $20.9 billion in 2024 to $43.5 billion by 2030, a compound annual growth rate of 13.1%, according to a new report by BCC Research. North America holds a 47.7% share, driven by institutional investment in genomic research and a mature biopharma ecosystem. Key drivers include AI and cloud computing integration, rising demand for personalized medicine and oncology applications, and emerging technologies such as long-read sequencing and single-cell multiomics. Major companies in the space include Illumina, Thermo Fisher Scientific, Agilent Technologies, and Dassault Systèmes.